The Immunology Therapeutic Area (TA) of Janssen Research & Development, LLC, has redefined the standard of care in immunology over the past two decades. Through the work of our dedicated team of scientists and drug developers, the TA has propelled Janssen to a leadership position with cutting-edge treatments that address the needs of millions of patients living with autoimmune and inflammatory diseases.
We have been working for more than 20 years in the discovery, development and commercialization of monoclonal antibodies. We offered the first anti-tumor necrosis factor (TNF) antibody, leading a class of new medicines that have changed the way chronic conditions in gastroenterology, rheumatology and dermatology are treated. Today, biologic medicines have been used to treat millions of patients worldwide across a broad spectrum of inflammatory diseases, targeting the underlying drivers of disease—not just the symptoms.
Our portfolio of large molecule therapies in immunology is unmatched. In addition to establishing anti-TNF-alpha therapy, we demonstrated the essential roles for inhibiting interleukin (IL)-12 and IL-23 in immune-mediated inflammatory diseases. We continue to strive to break new ground, and we are expanding our research into challenging areas where high unmet medical needs remain. We have also expanded our portfolio beyond monoclonal antibodies to include novel, oral small molecules and new biologic platforms.
Our scientists in research and clinical development work closely with medical affairs and commercial teams to enable a cycle of learnings that run from bench to bedside and back to bench, with a common goal—advancing science to improve the lives of patients. The scope of our work includes discovery based on deep scientific understanding of the diseases we treat.
We look to remain a leader in optimizing and tailoring therapeutic advances to target the right treatment for the right person in every part of the world.